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Summary
In order to determine their value for estimating the heparin concentration in
plasma, we established the relationship between test result and heparin concentra-
tion in plasma from various individuals, for five assays used with heparin treatment.
Only assays which can be carried out routinely in clinical laboratories were consid-
ered. The thrombin time and the whole blood recalcification time give pointless and
ambiguous information respectively, concerning the heparin level. The activated
partial thromboplastin time with and without heparin neutralisation give only a
rough estimate. The spectrophotometric method using a chromogenic substrate gives
the best information. The latter can be improved by using a non-linear (parabolic)
equation for the calculation of the reference curve. Current heparin therapy, con-
trolled with the aid of a clotting assay, may result in plasma heparin concentrations
that vary widely from one patient to another.
Introduction
Since the aim of heparin therapy is to abolish inappropriate clotting, the dose of
heparin is usually based on the result of a clotting assay. Often, this assay gives the
physician insufficient information to prevent the risk of an inadequate or excessive
dose, resulting in thrombosis or haemorrhage. The probability of haemorrhage
during heparin therapy has been reported to correlate better with the heparin
concentration than with the clotting potency of heparinised plasma []. Therefore
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one should be able to estimate these levels with an acceptable degree of precision.
The relationship between heparin dose and heparin plasma level, as well as the
relationship between heparin plasma level and therapeutic or prophylactic effect can
be determined only by means of a clinical trial. A heparin determination, that is
accurate and easy to perform in clinical laboratories. is a prerequisite for such a trial.
Titration methods and clotting assays employing the anti-Xa activity are too
laborious. Other available heparin assays used for establishing the dose of heparin
do not give insight into either of the relationships mentioned above. Knowledge of
the plasma heparin level is essential for this; therefore, a suitable assay is mandatory.
The purpose of this investigation was to determine the inter-individual variation
in the relationship between heparin concentration and its effect on the outcome of
several assays. The following methods were investigated: thrombin time (TT), whole
blood recalcification time (RCT), activated partial thromboplastin time (APTT),
APTT with heparin neutralisation (APTTHN) and a chromogenic substrate method
(csM).
Materials and methods
Blood samples
From I I arbitrarily chosen out-patients, not receiving heparin and showing no
abnormalities in a routine check of haematological and clotting measurements, 4
tubes of venous blood were collected by means of a vacuum system. The first tube
(Venoject, purple stopper, 2.7 ml, 3.3 mg di-K-EDTA) was used for haematocrit
determination with a Coulter Counter S * . The next 3 tubes (Venoject, black
stopper, 4.5 ml, 3.8% Tri-Na-citrate) were used for the other tests.
Heparin
Heparin was obtained from Leo,'Emmen, Holland. According to the manufac-
turer, the solution contained 5000 USP U /l of the sodium salt. Dilutions were made
in 0.154 mol/l NaCl.
To each of 7 tubes, containing 50 pl diluted heparin solution, 950 pl of citrated
blood were added. The heparin concentrations were chosen to make final concentra-
tions of 0 and approximately 50, 150, 300, 600 and 800U of heparin/l blood. For
the citrate blood (RCT) and citrated plasma (all other assays), the exact plasma
heparin concentration was calculated from the haematocrit. We obtained heparin
levels of approximately 100,250, 500, 1000 and 1500U/l plasma.
Platelet poor plasma
This was obtained by centrifugation of the 7 citrated blood tubes (10 min,
3500 X g, room temperature). This yielded less than 3 X l0e platelets/l.
The following assays were performed in duplicate at 3J"C, within 3 h of vene-
puncture.
RCT
The clotting time was measured after adding 200 p.l citrated blood to 200 pl
pre-warmed calcium chloride (0.32 mol/\) in a glass tube. This tube was tilted every
15 s. The end-point was the first observation by the medical technologist of a clot in
the tilted tube.
TT
The clotting time was measured after mixing 100 pl thrombin (38/m1, Roche)
with 200 pl pre-warmed plasma in a plastic tube. The end-point was the automatic
registration of a fibrin thread by the 'coagulometer' (Salm en Kipp), testing every
0.5 s.
APTT
For the APTT, 100 pl plasma were incubated for 3 min at 37oC with 200 p'l
cephalin-kaolin reagent (Diagen). The clotting time was measured after addition of
100 pl calcium chloride (0.025 mol/l). The end-point was the same as for the TT.
APTTNH
This was performed as described by Hoffmann and Meulendijk [2]. The APTT
was repeated after the heparin level had been increased by a known value. Then it
was performed again after neutralising the heparin with 10 prg hexadimethrine
bromide per assay (Polybrene, Sigma Chemical Co.).
CSM
This was performed as described by Teien and Lee [3], with some minor
modifications. In a glass cuvette of a programmable analyser (PA800 Vitraton), 50
pr,l plasma (l * 9 diluted with Michaelis buffer) were incubated with 350 p.l factor Xa
(7 nkatal/ml buffer, Kabi). The Xa buffer (pH 8.4 and I 0.2) contained di-K-EDTA
(75 mmol/l), Tris-HCl (50 mmol/l) and NaCl (175 mmol/l). After 3 min 40 s, 100
prl substrate-solution (0.2 mmol/l 3-2222 Kabi) were added and the rate of change
of extinction at 405 nm was determined Ïor 20 s. With a series of known heparin
concentrations in pooled human plasma, reference measurements were performed.
By the method of least squares a linear reference curve was calculated from these
measurements. Unknown heparin levels were read from this curve. Alternatively, a
parabolic reference curve was used for the calculation (see below).
Statistics
Bartlett's test was applied to test the homogeneity of the variances at different
heparin levels. If inhomogeneity was proven, the logarithms of the data were used, as
these proved to be more homogenous. The experimental variances (S.2-o) of three
assays (RCT, APTT, CSM) were calculated from the results of duplicate experi-
ments. The pooled inter-individual variances (Sí,) of the test results at three heparin
levels were calculated using one-way analysis of variance [4]. Sí, was compared with
Síe (divided by 2, since the mean of the duplicates were used) by means of Fisher's
test. The differences in the means of the test results at the three heparin concentra-
tions were compared with Sl,.
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Results
For each of the 6 methods we used the following procedure to obtain the data
presented.
'Each test result was plotted against the plasma heparin concentration and data
points derived from the same patient were connected by u ttruight line (these lines
represent 2-point interpolation). Then we determin ed, at 20 lJ 7l intewals, the test
result related to heparin concentràtions from TU/l to the highest available con-
centration' At each interval we calculated the mean and standard deviation (SD) of
the individual test results of the plasmas (these test results are mainly interpolated
but never extrapolated). A dashed line represents those mean values (Figs. l-6). For
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Figs' 1-6' Relationship between plasma heparin concentration and test result. Data derived from thesame patient are connected by a solid line. The means of the interpolated data areshown by a dashed line.A dotted line indicates that the plasma failed to clot at the next higher heparin concentrations tested.Fig' I' Thrombin Time' Fig.2-.Recalcification Tirhe (whole blood). Fig.3. Activated partial rhrombo-plastin Time' Fig.4. Activated Partial rhromboplastin Time with ir"pirin Neutralisation. Fig. 5. chro-mogenic Substrate Heparin,assay utith s-2222, applying a linear reference curve. Fig.6. chromogenicSubstrate Heparin assay with 5-2222, applying u pu.rtoti" reference curve.
further interpretation we considered this line as an,,aveÍaged response,, curve. The
estimated inter-individual variation in test result is reprelented ïy a shaded area(mean -t_ 2 SD).
- 
In all figures' except Fig. 2, one may note a shift of the curves to the right of
between 0 and 150 u/r. Trtts is presumabry due to neutrarisation of heparin by
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platelet factor 4. A deviation of between 0 and at least 150 U /l may be expected in
the assays.
We compared the heparin concentrations, obtained by applying an "averaged"
response line with those obtained by applying each individual response line (Table I).
The heparin level corresponding to a given test result can easily be read from the
abscissa via the dashed lines in the figures. For instance in Fig.2 an RCT value of
295 s is related to 500 U/l plasma. From the same figure we read, however, that at
295 s the actual heparin concentration in the plasmas range from 190 to 1035 U /1.
Table I gives the standard deviations of the individual test results and ranges of the
actual heparin concentration for 5 assays at 5 heparin levels. For better comparabil-
ity the SD is presented in IJ heparin/l plasma. Transformation was performed
according to the slope of the dashed line at that heparin level. At a given test result
the heparin levels in the 1l plasmas vary widely. The variations in test results differ
from assay to assay. The wide inter-individual variation can hardly be ascribed to
the experimental variation, since the latter amounts to only 107o or less of the
interindividual variation (Table II). There is a significant difference (p< 0.0001)
between the means of the test results of all assays except the Thrombin Time, at low
(150 U/l), medium (550 U/l) and high (900 U/l) heparin levels (Table III). The
larger the F-value, the larger the differences between the test results at the chosen
heparin levels compared to the inter-individual variance and the better a single test
can be interpreted. From the -F-values as well as from the figures it is obvious that a
TABLE I
STANDARD DEVIATION AND RANGES OF ACTUAL HEPARIN CONCENTRATIONS AT
FIVE HEPARIN LEVELS
For each method the test results at five heparin levels were read from the individual response curves. The
standard deviation was calculated and for better comparability transformed to U heparin/l plasma. The
number of data points is given in parentheses for each calculation. The mean test result at each heparin
level was read from the averaged response curve. The range of the actual heparin concentrations (U /l) at
this mean test result (read from the individual response lines) are presented just below the standard
deviation.
Assay Heparin level
0 u/l 300 u /l s00 u /l 800 u/l 1000 u/l
RCT SD (z)
range
APTT
APTTHN
CSM linear
CSM parabolic
368 (e)
1 90- 1035
104 (1  l )
290-805
1 5 7  ( l l )
365-800
7 e  ( 1 1 )
420-675
84 (8)
39s-60s
385 (e)
305- > 1400
3 1 3  ( 1 1 )
353- > 1500
128 (9)
550- > 1 500
ls3  (1  l )
64s- 1090
1 1 r  ( 8 )
620- 93s
3e0 (e)
400- >> 1400
265 (8)
640- >> 1 500
1000 (5)
620- >> 1 500
203 ( r  l )
740- > 1400
83 (8)
'775-  1110
s4 (1  l )
0-210
57 (1  1 )
0-155
0  ( r 1 )
0-0
85 (1  1 )
0- 120
3l (8)
0-80
185 (10)
1 10-830
85 (1  1 )
150-450
62 (11)
235-395
55 ( r  1 )
200-44s
5e (8)
220-420
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TABLE II
COMPARISON OF EXPERIMENTAL VARIANCE (SáP) AND INTER-INDIVIDUAL VARIANCE(Sí.)
For the RCT and APTT a logarithmic transformation was used,,since the individual variance varied withthe value' Thelabulated S.*o and S,,, are therefore coefficients of variance. For the AprTHN, linear andparabolic CSM the S.*o and-S,n, are tabulated as U/l
Assay S."o Sir, r(df1,df2)=
s?- rn t
r"ï Corresponding p-value
RCT
ATTIT
CSM linear
2%
2.7%
7.6 U/l
22%
277o
r0r u /l
F(30,7r)=p6
F(30,72):164
F(30,39):t7s
<0.0001
<0.0001
<0.0001
single test result of the Aprr and certainly of the csM can be more reliablyinterpreted than the TT, the RCT or even the APTTHN.
_ Although only slighrly proronged ar 100-150 rJ/r, ar plasmas fail ro showclotting at 200 u /lin the TT test (Íig. l). These findings agreË with rhose of pizzutoet al. [5].
The mean RCT without heparin is 165 s. A fixed prolongation factor of r.5 or 2(250 or 330 s, both wide^ly 
ryed) as target value corresporro, with heparin levelsranging-from 125 u /1 to 850 rJ /1 or trom zso u /l to t+oo u )t,respectrvely (Fig. 2).Fig. 3 shows that an Aprr of 100 s, which is 2.5 times prálorrgec corresponds toheparin concentrations ranging from 200 u /l to 650'u /1. 
'1l- 
tzos (3 timesprolonged), the heparin concenrrations range from 300 u 7t to g50 U/1. Thestandard deviation inu/rread from the curve of means is so, so, 100 and 200 u/laÍ 0,250,500 and 800 IJ/1, respectively.
If the result of the AprrHN as calculated by this method, lies between 2g0 u /l
TABLE III
COMPARISON OF TEST RESULTS AT THREE HEPARIN LEVELS
The means of test results at heparin concentrations of 150, 550 and 900inter-individual variance.
U /l arc compared with
Assay Mean value of test result at F (2,30)
between
Corresponding
p-vahte
tso u /l 5s0 u /l 900 u/1
RCT
APTT
APTTHN
CSM linear
CSM parabolic
195 s
5 2 s
66u/1
80 u/l
66 U/l
295 s
132 s
372 U/1
s80 u /1
372 U /1
379 s
224 s
s62 U/l
8e3 u/l
887 U /1
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
22.6
r04
7 l
180
190
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and 340 U /l then the actual heparin concentration in these 1l plasmas is between
300 U /l and 600 U /1. The standard deviation at 0,250 and 500 U /l is 0, 153 and
354 U /1, respectively.
The amidolytic method shows a standard deviation of 63, 69, 88 and 127 at
0U /1,250 U /1, 500 U /l and 800 U/1, respectively. At test results between 360 U /l
and 650 U /l no plasma has a concentration over 800 U /1 or under 300 U/l (Fig. 5).
At a result of 975 U /l the heparin levels range from 750 U /1to 1500 U/1. Using a
parabolic equation for calculating the reference curve the heparin concentrations
range from 775 U/1 to 1075 U/l (Fig.6).
Discussion
We investigated the inter-individual variation in test results of assays used to
determine dosage of heparin. Therefore we spiked the blood of I I individuals with
known amounts of heparin and determined the plasma heparin concentration using
five different methods. Relatively few attempts have been made to define an optimal
therapeutic or prophylactic heparin concentration. In general, levels between 50 and
200 U /l plasma are considered to be prophylactic and levels between 300 and 800
U/l plasma to be therapeutic. The results of a heparin assay should therefore give
sufficient information to differentiate plasmas containing 0, 300, 500, 800, and 1000
U/7, respectively. Considering heparin concentrations of 150, 550 and 900 U/l
inadequate, sufficient and excessive respectively, we evaluated the usefulness of 5
assays. A good assay allows an unambiguous classification into these groups,
without variation between patients.
In neither the prophylactic (0-200 U /1) nor the therapeutic range (300-800 U/D
does the TT give useful information about the heparin level. As a routine laboratory
determination for testing a heparin concentration, the TT gives pointless and the
RCT gives ambiguous information. The former only reveals whether the heparin
concentration is above or below 250 U /1, approximately; the latter gives no useful
information, due to the wide variation in the response of different plasmas. Use of
the RCT as a routine check in heparin therapy may lead to dangerous clinical
sequelae and must therefore be strongly discouraged.
The APTT gives sufficient information to monitor patients at 300 U /1, but an
overdose (above 1000 U/l) can easily be missed. In normal subjects, the relationship
between heparin concentration and its effect on the APTT can be estimated from
haematocrit and base-line APTT [6]. It is not practical to use the pre-heparin
clotting value as a base-line value, since the majority of patients treated with hqparin
are surgical cases. During operations the blood loss, clotting, infusion of blood,
plasma or saline will alter the haematocrit and the concentrations of clotting factors.
Following surgery one would not wish to leave a patient untreated simply to
determine a base-line value. Even with I I subjects it is clear that at a given test result
the actual heparin concentration is rather unpredictable. (A result of 140 s indicates
290 U /1in one plasma, but 805 U /l in another.)
The result of the APTTHN is expressed in U heparin /1 plasma as described by
Hoffmann and Meulendijk t2l. This method assumes a linear relationship between
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the APTT (s) and the heparin concentration(u/r) starting from 0U/1. Due to theshift in the range from 0 y1l:" 200 u /l mentioned aboue] this assumprion appearsto be incorrect. For the Aprr, 3 out of r l plasmas did not crot at a, at 1000 IJ /l(Fig' 3)' Unfortunately, this fact made it impossible to 
"ul"uiut. 
rhe heparin con-centrarion by means of the AprrHN at g00 u /r. Hoffmann aná Meulendijk [2] hadthe same problem as can be deduced from their Fig. 28. Therefore this method is oflimited use.
,. Th" 
heparin assay with chromogenic substrates and an automatic analyser, offerslittle more than the Afrr nspeóiaily at results above g00 U/l rhis cSM racksreliability. This is partry due to the non-rectilineurrty oi 
-tt 
" 
reference plot (notshown), as previously reported [7]. The rogical 
"otrJqu"rr"" 
i, to tit a parabolathrough the reference points, resuiting in essentially more accurate readings. Theresults of this modification are shown in rig.6 (cSÀÁparaboric). This cSM matchedthe demands of an acceptable heparin assay as mentioned above.
Still, using the csM (paraboric) we found a standard deviation of 3r tJ /l insamples without heparin and a standard deviation 
"f 
l l l t/ii" ,amples containing800 u /1' choosing any one of the individual calibratián fines instead of the"averaged" reference curve would lead to the same conclusion of wide variations.This important inter-individual variation may be caused by the influence of varia_tions in the amounr of-l-laler:lfactor 4 (pf4) as weil u, uyit 
" 
irrfluence of varyinglevels of antithrombin III (AtIII). whethËr the test outcoÁe should be corrected fordeviating ATIII levels' remains to be investigated. rhe p.o"eá,rres for collectingblood- and preparing plasma cause pf4 release to a variable extent and may thereforeintroduce a considerable error in heparin determination, due to neutralisation ofpart of the heparin by this pfa [3]. It also remains to be investigated whether andhow this can be avoided in the clinical laboratory.
currently, a fixed prolongation of clotting time (Aprr) is used as a target varuefor heparin therapy, rather than heparin concentration. This prorongation may beexpressed in seconds of as a. ratio with respect to a referenc. ,rulrr". The target valuemay vary between laboratories, but in each hospital it is fixed and mostly patient_in_dependent' The results of our investigation clearly demonstrate that this regimenmay result in plasma heparin concentrations, which vary widely from one patient tothe other.
Acknowledgement
The authors wish to thank p.M.M. van Haard, ph.D. and E.A. Sluyter M.D. fortheir critical and helpful assistance in translating the manuscriot.
References
I Holm HA' Heparin concentration (s-2222) and effect of heparin treatment. In:Lijnen HR, collen D,verstraete M, eds. Deveropmentsin haematology. The Hague, Martinus Nijhof: r9g0; r:63_69.2 Hoffmann JJML, Meulendijk PN. Plasma h"p#n' À simple, one-sample determination of both effect
iil_:;i:"""ion 
based on the activated partial thromboplastin time. Clin Chim Acta 1979; 81:
2'70
3 Teien AN, Lee M. Evaluation of an amidolytic heparin assay method. Thromb Res 1977; l0: 399-410.
4 Snedecor GW, Cochran WG. Statistical methods. Iowa U.S.A., The Iowa State University Press, 1973i
6th ed.
5 Pízzufo J, Garcia-Medez S, de la Paz Reyna M, et al. Thrombin time dilution test: A simple method for
the control of heparin therapy. Thromb Hemostas 1979; 42: 1276-1,285.
6 Whitfield LR, Lerry G. Relationship between concentration and anticoagulant effect of heparin in
plasma of normal subjects. Clin Pharmacol 1980; 28: 509-516.
7 Aiach M, Nussas C, Mardiguian J. Effect of some experimental conditions on the activity of a low
molecular weight heparin fraction compared to a high molecular weight fraction. Thromb Hemostas
l98l :  46:236.
l
I
t
